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Abstract: Purpose. The saliva concentration of xylitol released from two chewing gums was recorded,
the first containing xylitol as the only sweetener (100% xylitol) and the second containing only 22%
of the polyol. In addition, the in vitro antibacterial effect of the two chewing gums was evaluated.
Materials and Methods. The salivary concentration of Xylitol in 32 subjects was determined before and
at 0.30, 1.00, 2.00, 5.00, and 10.00 min while using the chewing gums, and at 15.00, 20.00, and 25.00 min
after the gums were discarded. In vitro antibacterial activity was determined on a pooled subgingival
plaque sample obtained from four patients with periodontal disease. Cariogenic and periodontal
bacteria were evaluated before and 15 min, 60 min, and 24 h after gum contact. Results. Using the
100% xylitol chewing gum, saliva levels increased bimodally, one peak after 30 s (1.49 ± 1.41 logµg/L)
and a second one at a 10-min evaluation (1.41 ± 1.11 logµg/L); the 22% chewing gum peaked only
two minute after contact (1.21 ± 1.24 logµg/L). Overall, a statistically significantly higher salivary
concentration of xylitol was detected using the 100% xylitol gum. All bacteria decreased after the
addition of the two chewing gums; the 100% gum achieved a greater decrease than the 22% gum.
Conclusion. The use of both chewing gums increased the concentrations of xylitol in saliva, with a
statistically significantly higher concentration using the 100% xylitol gum. Cariogenic and periodontal
bacteria were reduced by both chewing gums; 100% xylitol gum produced the highest and longest
lasting effect. This study opens up to the use of xylitol against periodontal disease.
Keywords: xylitol; saliva; oral bacteria; sub-gingival plaque; antimicrobial effect; chewing gum
1. Introduction
Dietary fermentable carbohydrates are among the main triggers for the development of cariogenic
biofilm [1]. Several preventive strategies are recommended to control the risk of caries; dietary changes,
with reduce intake of sweetener and the use of sugar substitutes, are probably among the most
suggested [2].
Several benefits of polyols, particularly xylitol, have been suggested for general and oral health,
such as increasing tight junction and barrier formation of the skin, modulating intestinal microbial
composition, reducing nose, throat, and ear bacterial infections, influencing bone health, stimulating
immunity, and increasing metabolic health [3].
Consumption of polyol, particularly xylitol, through chewing gum or tablets, is reported to
reduce dental plaque, the concentration of cariogenic bacteria, such as mutans streptococci, leading to a
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reduced caries increment [4,5]. Although the xylitol mechanism is not fully known, several studies
demonstrate the benefits on caries both in children and adults, showing that the polyol possesses
both noncariogenic and cariostatic properties. The supposed effective daily dose of xylitol is between
three and eight grams and frequent and prolonged intakes are recommended to obtain long-lasting
benefits [2]. The anti-caries effect of xylitol is associated with suppression of mutans streptococci and
modification of their virulence [5,6].
When xylitol is administered, the frequency of administration, the dose-response, and the minimal
salivary concentration are important parameters that have to be assessed. However, only afew studies
have evaluated the concentration of polyol in saliva after the intake of products containing xylitol,
with discordant results [7–9]. Since there are no clear indications of salivary concentrations after the
intake of different products, this can lead to using these products in a way that is not optimal for
achieving the complete release of xylitol (e.g., mastication time of chewing gum might be not sufficient
to ensure the complete release of the polyol); it is of high relevance to obtain reliable data on salivary
xylitol concentrations.
While a fairly large number of studies have been conducted on the effect of xylitol administration
on caries-associated bacteria [9–12], few studies include the effects of this polyol on other oral strains,
such as those associated to periodontal disease [13,14]. In these studies, although xylitol consumption
has been shown to reduce the streptococci counts, it has not affected the bacterial composition of
the dental plaque. Therefore, the acquisition of information on the antibacterial activity of xylitol on
different bacteria strains (i.e., periodontal bacteria and other oral saprophytes) is of extreme interest.
This work aimed at assessing the salivary concentration of xylitol released from two chewing gums
containing different amounts of the polyol in a sample of healthy volunteers. In addition, the in vitro
antibacterial effect of xylitol chewing gum was tested against different strains of oral microorganisms
related to caries and periodontal disease.
2. Materials and Methods
2.1. Study Design
This study took place in Sassari (Italy) and lasted from February 2018 to May 2018. The study
was approved by the Ethics Committee of the University of Sassari (SS-15884-GC 23/ 09/2017) and
registered at http://www.clinicaltrial.gov (Protocol Registration Receipt NCT03971981) and conducted
in accordance with the Declaration of Helsinki (http://www.wma.net).
The research protocol was conducted in two phases (Figure 1). In the first, an in vivo double-blind
cross-over study was performed to measure the salivary concentration of xylitol released from two
types of chewing gum containing different amounts of the polyol. The study had a cross-over design:
the first half of the sample used the chewing gum with xylitol as the only sweetener (100% xylitol
chewing gum) and the other half used the chewing gum with xylitol among the sweeteners (22% xylitol
chewing gum); after a 7-day wash-out period, the two sub-groups reversed the types of chewing gum.
Subjects were instructed to consume the products as they normally do. Throughout the study the
subjects were not allowed to use mouthwashes, other xylitol products, antimicrobial medications, etc.
In the second phase of the designed protocol, the antibacterial efficacy of the two types of chewing
gum was tested in vitro against nine different strains of oral bacteria.
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Figure 1. Flow-chart of the study design (in vivo and in vitro phases).
All chewing gum used in this investigation were produced and supplied by Perfetti Van Melle
SpA (Lainate, Italy) and are commercially available in Italy. Except for the sweeteners, the two chewing
gums were identical in weight (1.4 g), shape, color, and packaging. Their composition is displayed in
Table 1.
Table 1. Percentage Composition of the two chewing gums. Each chewing gum weights 1.4g.
Ingredients 100% Xylitol 22% Xylitol
g/% g/%
Xylitol 0.903/64.5 0.308/22
Sorbitol - 0.434/31
Maltitol Syrup - 0.084/6
Mannitol - 0.056/4
Gum base 0.421/30.1 0.392/28
Other components 0.076/5.4 0.126/9
The xylitol amount was entirely contained in the hard coating for the 22% chewing gum, while
the 100% xylitol gum contained the same amount in the hard coating and the remaining part in the
gum pellet.
2.2. Xylitol Concentration In Saliva
2.2.1. Sample Size
In the literature, only a few studies reported data on the concentration of xylitol in saliva [7–9].
Since no study reported a sample size calculation and two of them have a very small number of
participants, it was decided to use the study performed in Finland as reference [9]. Since the present
study has a double-blind cross-over design, the sample size calculation was performed through
G*Power 3.1.3 for Apple, usi g logistic regr ssion wit an odds rati of 1.8 and an error probability of
0.04. The minimum sampl size w s set to 28 subjects; the number was then increased tak g into
account the uncertainty of the effect and the no-responders rate; the number of subjects was set to 38.
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Fifty dental students (age range 19–25 years), attending the Dental School of the University of Sassari,
were invited to participate with a leaflet explaining the purpose of the study together with an informed
consent; thirty-three accepted. The inclusion criteria were good general health, absence of diseases that
could alter the saliva secretion rate, as assessed by a medical questionnaire, a stimulated saliva flow of
at least 1 mL/min, and no medication in the six weeks before the beginning of the study. Smokers were
not included. One of the authors (OM) performed all the examinations and registered medical and
dental histories.
2.2.2. Samples Collection and Measurements of the Concentration of Xylitol in Saliva
The saliva flow rate was measured in the mid-morning at least one hour after each participant
had taken any food. Subjects were asked to chew a piece of paraffin wax for 1 min and then spit
into graduated tubes for 5 min. Thirty-two subjects showed a saliva flow ≥ 1 mL/min and were
finally enrolled.
Xylitol concentration was determined through a spectrophotometer analysis (Agilent Technologies
Cary 60 UV-Vis, using a wave-length of 492 nm) in saliva samples collected before and during chewing
gum use at 0.30, 1.00, 2.00, 5.00, and 10.00 min (stimulated saliva sampling); then the chewing gums
were discarded and further samples were collected at 15.00, 20.00, and 25.00 min from the start
of chewing (unstimulated saliva sampling). A minimum of 0.5 mL of saliva was collected at each
time point.
The concentration of xylitol was determined by the oxidation of nicotinamide-adenine dinucleotide
(NAD+) to D-xylulose in the presence of xylitol dehydrogenase (SDH) with the formation of reduced
nicotinamide-adenine dinucleotide (NADH) [15]. Saliva samples were first de-proteinased adding
to a 200 µL of saliva an equal volume of ice-cold 1 M perchloric acid and centrifuged at 1500 g for
10 min and the supernatant was then neutralized with 1 M KOH. The sample obtained was treated as
follows: 200 µL of the sample was added to 10 µL of distilled water in a sterile 1.7-mL Eppendorf tube
followed by 50 µL of buffer solution (pH 8.6). Then 20 µL of NADH iodonitrotetrazolium chloride and
0.2 µL of diaphorase were put into the solution. The reaction started with the addition of 0.5 µL of
SDH. The absorbance of the solutions was read at the end of the reaction (approx. 15 min). Formazan
crystals were dissolved by addition of 0.5 mL of lysing solution, and after a 3-h incubation at room
temperature, 100 µL of the suspension was added to each sample that was measured by the increase in
absorbance at 492 nm. The smallest differentiating absorbance for the assay is 0.005 absorbance units.
All salivary Xylitol concentration data were expressed in µg/mL.
2.3. Antibacterial Activity of Xylitol
The in vitro antibacterial activity of the two types of xylitol chewing gum at different concentrations
(22% and 100%, respectively) was determined on a sub-gingival pooled plaque sample collected from
four patients affected by periodontal disease attending the Periodontal Department of the Dental Clinic
of the University of Sassari. An informed consent, explaining the purpose of the study, was obtained
from the four volunteers.
2.3.1. Methods
None of the subjects used antibiotics or had undergone periodontal treatment during the 4 months
before the sampling; participants were required to refrain from eating, drinking, smoking, or brushing
their teeth after midnight on the day of the sampling. The volunteers rinsed their mouth with water,
and the deepest pocket (4–7 mm range of pocket dept and 1–2 mm of attachment level) of each quadrant
was chosen for sub-gingival plaque sampling. The sites of collection were isolated with cotton rolls,
and supragingival plaque was gently removed with curettes and dried with air. Sub-gingival plaque
was taken by the insertion of sterile paper points for 15 s. The paper points were transferred to 250 mL
of reduced transport fluid (RTF) [16,17], and vortexed together for 30 s; the supernatant and the paper
points were removed and the pellet re-suspended in 100 mL of twice-distilled water. Aliquots were
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measured in a spectrophotometer in 1-mL cuvets (one optical density unit was considered≈109 cells/mL
at 600 nm). Twenty g/L trypticase soy agar (Sigma-Aldrich, Italy), 26 g/L brain–heart infusion (BHI)
agar (Difco, USA), 10 g/L yeast extract, 5 mg/L hemin, and 20% sucrose (w/v) were mixed to prepare
a medium. After sterilization and cooling, 5% defibrinated sheep blood, 5 mg/mL menadione, and
10 mg/mL N-acetylmuramic acid (Sigma-Aldrich, Italy) were aseptically added; 150 mL of the medium
was then dispended into one 96-well microtiter plate (Cellstar, Italy). The plaque broth (150 µL, or
%1.5·106 bacteria) was pipetted to fill into the blood agar wells. The plates were then incubated
anaerobically at 35 ◦C for 48 h, then the cultures were blotted out and the wells gently washed three
times with sterile PBS in order to remove nonadherent cells; this operation was repeated [16].
2.3.2. Specimen Preparation
Three samples of each chewing gum were grinded in a mortar with 30 mL of artificial saliva
(1.5 mM CaCl2, 1.0 mM KH2PO4 and 50 mM NaCl, pH 7.0) [18], during 5 min, then the final solution
was collected in a clean container. An amount of 2 ml of the solution were inserted in the wells.
Twenty-four wells were evaluated before adding the solution and then another 24 wells after 15 min,
60 min, and 24 h from the contact between the plaque sample and the chewing gum solution. Tris-EDTA
buffer (1.5 mL) was added to the plates and the bacterial colonies were scraped off the surface with
sterile L-shaped glass rods. The suspensions were placed into individual tubes (Cellstar, Italy) and
sonicated for 10 s. Each suspension was adjusted to a final optical density of 1.0, which corresponded
to %109 cells.
2.3.3. Microbiological Analysis
The analysis of bacterial species was performed using the checkerboard DNA–DNA hybridization
method [19–21]. Whole genomic probes were prepared from nine bacterial strains that are part of
supra and subgingival plaque biofilm, some of them related to caries, gingivitis, and periodontal
disease (S. mutans, S. sobrinus, P. intermedia, S. salivarius, S. mitis, B. forsythus, L. casei, L. salivarius,
and L. fermentum) [22,23]. An evaluation of the bacterial counts in the samples was performed by
comparing the obtained signals with the ones generated by the pooled standard samples containing a
count of 106 and 105 of each bacterial species, respectively. The signals were coded on a scale from 0 to
5 as follows: 0 = no signal; 1 = a signal density weaker than that of the low standard (<105 bacteria);
2 = a signal density equal to that of the low standard (=105 bacteria); 3 = a signal density higher than
that of the low standard but lower than that of the high standard (>105 but <106 bacteria); 4 = a signal
density equal to that of the high standard (= 106 bacteria); and 5 = a signal density higher than that
of the high standard (>106 bacteria). Further details regarding the technique might be found in the
literature [24,25].
2.4. Data Analysis
All data from both phases were imported into MS Excel and checked. From a brief analysis,
the salivary xylitol concentrations appeared with a high skewness, so to normalize the data, they
were logarithmically transformed before the analysis. Mean and standard deviation (± SD) for each
sampling point and the checkerboard scores were calculated using STATA 13 (StataCorp LLC, USA).
The comparison between the two types of chewing gum at each sampling time was performed
using one-way Analysis of Variance (ANOVA), while the intra-group comparison was evaluated
with two-way ANOVA. Due to the variability of the salivary concentration among subjects, the
internal-consistency reliability was calculated using Cronbach’s alpha statistic as post-hoc evaluation.
The data set is available in the Supplementary Materials. The level of statistical significance was set
at 5%.
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3. Results
No statistically significant differences were found in the xylitol concentration of saliva samples
collected before the use of the chewing gums (Table 2).
Table 2. Xylitol concentrations in saliva (µg/L). One-way ANOVA for the comparison between the two
types of chewing gum and two-way ANOVA for intra-group comparison. The values in bold are the
maximum peaks reached.
Time 100% Xylitol (logµg/L) 22% Xylitol (logµg/L) p-Value
Mean ± sd mean±sd
Before −0.68 ± −0.66 −0.66 ± −0.41 NS
30 s 1.49 ± 1.41 0.04 ± 1.20 < 0.01
1 min 1.39 ± 1.53 1.19 ± 1.38 0.02
2 min 1.09 ± 1.27 1.21 ± 1.24 0.03
5 min 1.28 ± 1.10 1.00 ± 1.19 0.02
10 min 1.41 ± 1.11 0.45 ± 0.64 < 0.01
15 min 1.19 ± 1.12 −0.08 ± 0.25 < 0.01
20 min 1.07 ± 1.03 −0.33 ± 0.01 0.02
25 min −0.30 ± −0.92 −0.92 ± −1.15 < 0.01
p-value < 0.01 < 0.01
The 100% xylitol chewing gum produced the highest salivary concentration after 30 s of use
(1.49 ± 1.41 logµg/L) and then the amount decreased after 1 and 2 min until a second increment was
detected at 5 and 10 min (1.28 ± 1.10 logµg/L and 1.41 ± 1.11 logµg/L, respectively); after that, a
slow decrease until 25 min was found. The 22% xylitol chewing gum produced the highest salivary
concentration after 2 min of use (1.21 ± 1.24 logµg/L) and then gradually decreased in the following
evaluations. Statistically significant differences between the concentrations produced by the use of the
two Xylitol chewing gums were recorded at all time points (p = 0.01 for the comparison after 1 min,
while p < 0.01 for all the other times). The modification of the concentration of xylitol in each group
during the different times was statistically significant (p < 0.01). The Cronbach alpha was 0.97 in the
100% xylitol group and 0.95 in the 22% Xylitol group.
The bacterial concentrations before and after the contact with the two xylitol chewing gums
(22% and 100% xylitol) solutions are reported in Table 3. All the considered bacterial strains decreased
after the addition of the two chewing gums solutions. The 22% xylitol obtained the highest decrease
(except for B. forsythus) after 60 min and then increased again at the last evaluation (24 h); the 100%
xylitol chewing gum obtained a greater decrease compared to the 22% xylitol at all time points; the
highest decrease was recorded after 24 h from the contact for all bacteria strains.
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Table 3. Mean concentration ( ± SD) of bacteria in sub-gingival plaque based on analysis of a 5-unit score. (1 = <105, 2 = 105, 3 = 105 > x < 106, 4 = 106, 5 = > 106).
Bacteria
Strain
Pre
Mean (SD)
15 min
Mean (SD)
60 min
Mean (SD)
24 h
Mean (SD) p-Value
100% Xylitol 22% Xylitol 100% Xylitol 22% Xylitol 100% Xylitol 22% Xylitol 100% Xylitol 22% Xylitol
S. mutans 3.49 ± 1.08 1.76 ± 0.60 3.15 ± 0.65 ˆ 1.32 ± 0,47 2.82 ± 0.72 ˆ 1.21 ± 0.43 2.96 ± 0.56 ˆ p< 0.01 p = 0.04
S. sobrinus 2.00 ± 0.65 1.20 ± 0.41 1.60 ± 0.70 * 1.11 ± 0.32 1.47 ± 0.66 1.06 ± 0.24 1.74 ± 0.66 ◦ p = 0.04 p = 0.02
P. intermedia 2.69 ± 1.12 1.68 ± 0.64 2.34 ± 0.82 ◦ 1.53 ± 0.61 1.95 ± 0.81 * 1.29 ± 0.46 2.29 ± 0.71 ˆ p < 0.01 p = 0.05
S. salivarius 2.11 ± 0.92 1.56 ± 0.50 1.84 ± 0.69 1.32 ± 0.47 1.69 ± 0.61 1.20 ± 0.41 1.91 ± 0.56 ◦ p = 0.02 p = 0.07
S. mitis 2.46 ± 1.11 1.56 ± 0.66 1.90 ± 0.75 * 1.41 ± 0.56 1.78 ± 0.65 1.12 ± 0.33 2.12 ± 0.59 ˆ p < 0.01 p = 0.02
B. forsytus 2.32 ± 0.94 1.41 ± 0.56 2.07 ± 0.51 * 1.35 ± 0.49 1.94 ± 0.50 * 1.17 ± 0.39 1.92 ± 0.47 ◦ p = 0.01 p = 0.09
L. casei 2.24 ± 1.05 1.38 ± 0.55 1.76 ± 0.70◦ 1.32 ± 0.47 1.75 ± 0.60 * 1.18 ± 0.39 2.67 ± 0.51 ˆ p = 0.02 p = 0.10
L. salivarius 2.5 ± 1,05 1.50 ± 0.62 1.95 ± 0.65 * 1.35 ± 0.48 1.68 ± 0.72 1.15 ± 0.36 2.03 ± 0.66ˆ p = 0.01 p = 0.08
L. fermentum 2.26 ± 0.90 1.38 ± 0.55 2.11 ± 0.50 * 1.26 ± 0.45 1.75 ± 0.49 * 1.21 ± 0.41 2.19 ± 0.46 * p = 0.02 p = 0.12
* p < 0.05; ◦p = 0.01; ˆp < 0.01.
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4. Discussion
The xylitol salivary level increased after the use of both types of chewing gum; however, the
100% xylitol gum achieved the highest decrease, as expected. The results of the in vivo study run
similarly to those available in literature [7–9]. Salivary xylitol concentrations were elevated for a short
period of time (less than 15 min) and then decreased, reaching almost the baseline level at the 25-min
evaluation. Xylitol concentration levels in saliva using the 100% xylitol chewing gum did not decrease
as linearly as using the 22% gum, but bimodally. This difference could be related to the different
distribution of the polyol in the gum: in the 100% the highest amount of xylitol was included in the
gum pellet, while in the 22% it was only contained in the hard coating, as described in materials and
method. It is, therefore, reasonable to have a second peak concentration after some time from the
start of chewing. The sampling technique, stimulated and unstimulated saliva, was postulated as the
reason of the bimodal fashion release concentration [7]. In this study, the second peak was observed at
the end of the chewing period; chewing saliva stimulation is reduced after 5 min and this may have
influenced the presence of the bimodal release concentration; as reported in literature, the highest
salivary concentration of drugs (fluoride, nicotine, etc) released from gums was detected between 5
and 10 min from the beginning of use [26–29].
On the other hand, the skewed distribution of the salivary Xylitol concentration must be taken
into account since high inter-subject variability has been observed. This outcome can be explained by
several parameters, such as chewing distance, chewing frequency, and the twisting motion of the gum
affecting the xylitol release [29]. These parameters were not included in the analysis as subjects were
free to chew as they usually do.
A relatively high daily dose of xylitol is necessary to obtain positive effects [3–6,11–14,30–36].
The frequency of administration is also considered an important factor, since, as reported in this study,
its concentration in saliva tends to decrease in a short time. The hypothesis that Xylitol may have an
effect on dental plaque is related to the transport and phosphorylation of the polyol through the cell wall
by a constitutive fructose-PTS (phosphotransferase) system with accumulation of xylitol-5-phosphate
in intracellular substrate [35,37]. Whilst the current study was conducted in vitro using a pooled
sub-gingival plaque sample, significant differences in antibacterial composition were detected using
both chewing gums, although most impressive antibacterial actions were observed with the 100% gum.
The bacterial viability is reduced over the time of the experiment (24 h), and it was similar in both groups,
and the difference observed has to be mainly ascribed to the different concentration of xylitol in the gums.
Few studies have focused on the effect of polyols on oral bacteria apart from cariogenic ones [11,31,38].
Xylitol proved to clinically reduce the amount of dental plaque and gingivitis in children and young
adults [34,36,39]. In vivo, xylitol chewing gum was able to decrease mutans streptococci levels [39],
while in vitro, Xylitol has shown to inhibit the growth of several bacterial strains like Streptococcus
mutans, Streptococcus sobrinus, Lactobacillus rhamnosus, Actinomyces viscosus, Porphyromonas gingivalis,
and Fusobacterium nucleatum [32,37,38,40] with different effect on different strains. Xylitol is able to
inhibit the production of inflammatory and proinflammatory cytokines derived from periodontal
bacteria as Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans [13,40–42].
This study has potential limitations. First of all, it is necessary to consider the single administration
in the in vivo phase of the study. It is likely that the use of the gums several times a day may also
modify the amount of Xylitol in the mouth over a longer period. A trial that examines the use of
gum for prolonged periods is necessary to support this hypothesis. Taking also into account the high
variability in the salivary concentration of Xylitol observed among the different subjects, it would be
useful to repeat the study involving a higher sample.
A third limitation could be the detection method used (spectrophotometry), different from those
used in other studies (High-performance liquid chromatography or enzymatic assay using a polyol
dehydrogenase-based procedure), which makes the present findings quite difficult to compare to the
previous ones [13,16,41]. In favor of the test method used here, is that spectrophotometry detects lower
levels of xylitol (0.1 g/mL) than the other two.
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A further limit could be the study design of the in vitro part: it does not reflect real life conditions.
The bacterial effect was measured with a continuous and direct contact between the xylitol solution
derived from the two chewing gums and the bacteria strains for a period that does not reflect the
real situation.
Diversely, this is the first paper, to the authors’ knowledge, which evaluates and describes an
antibacterial effect of xylitol-containing chewing gums on multiple strains in a pooled sub-gingival
plaque sample.
5. Conclusions
Xylitol is a well-known caries preventive agent when applied via chewing gum. This study
reports data on the in vivo salivary concentration of xylitol after the use of chewing gums, containing
different amounts of the polyol, and the in vitro activity of the same types of chewing gum against a
spectrum of oral bacteria.
The use of both types of chewing gum increased the xylitol salivary concentrations for a short
period of time with a statistically significantly higher level using the 100% xylitol gum. The bacterial
strains related to caries and periodontal disease from sub-gingival plaque were reduced in vitro by the
two xylitol chewing gums with a higher and long-lasting reduction for the 100% xylitol gum. This
study opens up to the use of xylitol against periodontal disease.
Supplementary Materials: The following are available online at http://www.mdpi.com/2076-3417/10/8/2900/s1,
Date set.
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